Which of the following medications is NOT typically used for the treatment of TB?

Which of the following medications is NOT typically used for the treatment of TB?

• A. Rifampin
• B. Ethambutol
• C. Atovaquone
• D. Isoniazid

Answer: (C)

Atovaquone is not typically used for the treatment of tuberculosis (TB). Instead, it is primarily an antiprotozoal medication, commonly utilized for the treatment and prevention of pneumocystis pneumonia and certain parasitic infections, such as those caused by the protozoan parasite Toxoplasma gondii. In contrast, the other medications listed—Rifampin, Ethambutol, and Isoniazid—are established first-line agents in the treatment regimen for TB. These drugs work synergistically to effectively combat Mycobacterium tuberculosis, the bacterium responsible for TB. Rifampin is a potent antibiotic that inhibits bacterial RNA synthesis, while Isoniazid disrupts the synthesis of mycolic acids, essential components of the bacterial cell wall. Ethambutol primarily works by inhibiting the synthesis of the cell wall. Thus, Atovaquone’s lack of relevance in TB treatment is due to its specific action against protozoal rather than mycobacterial infections.

Atovaquone is not typically used for the treatment of tuberculosis (TB). Instead, it is primarily an antiprotozoal medication, commonly utilized for the treatment and prevention of pneumocystis pneumonia and certain parasitic infections, such as those caused by the protozoan parasite Toxoplasma gondii.

In contrast, the other medications listed—Rifampin, Ethambutol, and Isoniazid—are established first-line agents in the treatment regimen for TB. These drugs work synergistically to effectively combat Mycobacterium tuberculosis, the bacterium responsible for TB. Rifampin is a potent antibiotic that inhibits bacterial RNA synthesis, while Isoniazid disrupts the synthesis of mycolic acids, essential components of the bacterial cell wall. Ethambutol primarily works by inhibiting the synthesis of the cell wall. Thus, Atovaquone’s lack of relevance in TB treatment is due to its specific action against protozoal rather than mycobacterial infections.